Acute Kidney Disease, Acute Kidney Injury, Decision Support Systems, Clinical, Renal Insufficiency, Chronic
Conditions
Keywords
Acute Kidney Injury, Acute Kidney Disease, Chronic Kidney Disease, AKI, AKD, CKD, Decision Support Systems, Clinical, CDS
Brief summary
Strategies to stop AKI-AKD-CKD continuum - Policy is one of the collaborative projects, Strategies to stop AKI-AKD-CKD continuum, Epidemiology, Immunology, Repair, Artificial intelligence, and Policy (EIRAP). It is aimed to study effective interventional strategies that lower the incidence of CKD among patients with AKD. The intensified AKD care to reduce CKD (ISACC trial) is a prospective, open-labeled, randomized controlled trial is designed to evaluate the efficacy of multidisciplinary team care (MDT) model and acute kidney disease (AKD) clinic visits
Detailed description
Acute kidney disease (AKD), defined as the ongoing renal function impairment between 7 days and 90 days following AKI, has been proposed as a window of intervention to prevent the occurrence of CKD. However, the effective therapeutic strategies of AKD care remain to be developed. We intend to conduct a prospective, randomized, open-label, behavioral interventional trial to validate the efficacy of multidisciplinary team (MDT) care model which aims to improve AKD care and to reduce de novo CKD incidence.
Interventions
BEHAVIORALMultidisciplinary team (MDT) care and Acute kidney disease (AKD) clinic
Multidisciplinary team (MDT) care: NPDS care model Acute kidney disease (AKD) clinic: layered approach
Sponsors
National Health Research Institutes, Taiwan
Taipei Medical University
Taipei Medical University Shuang Ho Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 20 yrs * Severe AKD: Stage 2, Stage 3 and Dialysis-requiring AKD (AKD-D)
Exclusion criteria
* Pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of Major adverse kidney event | 90days | Proportion of MAKE * Renal progression to CKD * Chronic dialysis (any 1 outpatient dialysis after discharge) * Death |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Chronic dialysis | 90days, 180days, 360 days, 3years | Proportion of chronic dialysis |
| Renal progression | 90days, 180days, 360 days, 3years | Proportion of renal progression to CKD |
| Time to MAKE | 90days, 180days, 1year (360days) | Time to MAKE |
| Time to death | 90days, 180days, 1year (360days) | Time to death |
| Time to chronic dialysis | 90days, 180days, 1year (360days) | Time to chronic dialysis |
| Mortality | 30days, 60days, 90days, 180days, 360 days, 3years | Proportion of death |
| Time to first ER visit | 90days, 180days, 1year (360days) | Time to first ER visit |
| Time to first rehospitalization | 90days, 180days, 1year (360days) | Time to first rehospitalization |
| Time to first recurrence of AKI | 90days, 180days, 1year (360days) | Time to first recurrence of AKI |
| Proportion of MACE | 30days, 60days, 90days, 180days, 360 days, 3years | CVA, AMI, CHF, or cardiac revascularization procedure |
| Time to renal progression to CKD | 90days, 180days, 1year (360days) | Time to renal progression to CKD |
Contacts
Primary ContactMai-Szu Wu, MD
Backup ContactYu-Wei Chen, MD
Outcome results
None listed